CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $587,866 | -24.1% | 32,623 | -32.4% | 0.27% | -57.4% |
| Q1 2023 | $774,815 | -54.9% | 48,245 | -48.6% | 0.63% | -38.1% |
| Q4 2022 | $1,718,242 | -5.0% | 93,893 | +2.0% | 1.02% | -1.3% |
| Q3 2022 | $1,808,000 | +194.5% | 92,047 | +179.4% | 1.03% | +178.4% |
| Q2 2022 | $614,000 | -36.8% | 32,948 | -25.5% | 0.37% | -39.9% |
| Q1 2022 | $971,000 | -35.5% | 44,226 | -16.5% | 0.62% | -48.5% |
| Q4 2021 | $1,505,000 | +211.6% | 52,982 | +71.8% | 1.20% | +240.3% |
| Q3 2020 | $483,000 | +7.3% | 30,845 | +20.0% | 0.35% | -5.6% |
| Q2 2020 | $450,000 | – | 25,701 | – | 0.37% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |